Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.

Pareyson, Davide; Reilly, Mary M; Schenone, Angelo; Fabrizi, Gian Maria; Cavallaro, Tiziana; Santoro, Lucio; Vita, Giuseppe; Quattrone, Aldo; Padua, Luca; Gemignani, Franco; Visioli, Francesco; Laurà, Matilde; Radice, Davide; Calabrese, Daniela; Hughes, Richard A C; Solari, Alessandra

Pareyson, Davide; Reilly, Mary M; Schenone, Angelo; Fabrizi, Gian Maria; Cavallaro, Tiziana; Santoro, Lucio; Vita, Giuseppe; Quattrone, Aldo; Padua, Luca; Gemignani, Franco; Visioli, Francesco; Laurà, Matilde; Radice, Davide; Calabrese, Daniela; Hughes, Richard A C; Solari, Alessandra.

Affiliation

Pareyson D; Clinic of Central and Peripheral Degenerative Neuropathies Unit, Department of Clinical Neurosciences, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Foundation, Carlo Besta Neurological Institute, Milan, Italy. davide.pareyson@istituto-besta.it

Lancet Neurol ; 10(4): 320-8, 2011 Apr.

Article in En | MEDLINE | ID: mdl-21393063

Subject(s)

Antioxidants/therapeutic use; Ascorbic Acid/therapeutic use; Charcot-Marie-Tooth Disease/drug therapy; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Ascorbic Acid / Charcot-Marie-Tooth Disease / Antioxidants Type of study: Clinical_trials / Prognostic_studies Language: En Journal: Lancet Neurol Year: 2011 Type: Article Affiliation country: Italy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google